title: Relationship of endometrial thickness with the menstrual timing of leuprolide acetate administration for preoperative preparation for hysteroscopic surgery.
abstract: OBJECTIVE
  To assess the relationship of menstrual timing of administration of gonadotropin-releasing hormone (GnRH) agonist on the effectiveness of endometrial thinning and unwanted uterine bleeding.
  
  
  METHODS
  Prospective observational study.
  
  
  METHODS
  Gynecology department of a community hospital.
  
  
  METHODS
  One hundred consecutive women in a private practice, without submucous myomas, scheduled for transcervical endomyometrial resection or ablation.
  
  
  METHODS
  A GnRH agonist was administered at an unspecified time of the menstrual cycle. Transcervical hysteroscopic endomyometrial resection or ablation was performed 1 month later.
  
  
  RESULTS
  No significant statistical differences were seen in either the effectiveness of endometrial thinning or the occurrence or severity of unwanted uterine bleeding.
  
  
  CONCLUSIONS
  A GnRH agonist as pretreatment for endomyometrial resection or ablation can be administered at any time during the menstrual cycle with similar efficacy. Timing of surgery can be at the mutual convenience of patient and physician.
authors.affiliation: Department of Obstetrics and Gynecology, South Nassau Communities Hospital, Oceanside, New York, USA.
authors.forename: H G
authors.initials: HG
authors.lastname: Nathanson
authors.forename: D R
authors.initials: DR
authors.lastname: Phillips
authors.forename: S J
authors.initials: SJ
authors.lastname: Milim
authors.forename: J S
authors.initials: JS
authors.lastname: Haselkorn
authors.forename: A
authors.initials: A
authors.lastname: Kapra
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004717:Endometrium / Q000187:drug effects / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007044:Hysterectomy; D016729:Leuprolide / Q000008:administration & dosage*; D008595:Menorrhagia / Q000601:surgery; D008598:Menstruation / Q000187:drug effects* / Q000502:physiology; D008875:Middle Aged; D019370:Observation; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care / Q000379:methods; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide